TY - CHAP M1 - Book, Section TI - Molecular Targeted Therapies A1 - Miller, David Michael A1 - Reddy, Bobby Y. A1 - Tsao, Hensin A2 - Kang, Sewon A2 - Amagai, Masayuki A2 - Bruckner, Anna L. A2 - Enk, Alexander H. A2 - Margolis, David J. A2 - McMichael, Amy J. A2 - Orringer, Jeffrey S. PY - 2019 T2 - Fitzpatrick's Dermatology, 9e AB - The treatment strategy for human disease has evolved dramatically since 2000 as a result of advances in molecular genetics, cell biology, and pharmacology. Increased understanding of molecular pathophysiology has allowed for the development of therapeutics that interact with specific molecular targets associated with disease. Agents that are the product of rational drug design, in which compounds are deliberately designed to interact with a biologic target, are often referred to as “targeted therapy” and form one of the cornerstones of “precision medicine.” The potential of targeted therapy is perhaps best exemplified with oncologic disease, but the promise of rational drug design is beginning to be seen across all fields of medicine. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1161345477 ER -